June 3, 2023

Diabetes Associated Ophthalmic Treatment Market Share by 2030

The global diabetes associated ophthalmic treatment market size is expected to be worth around US$ 50.7 billion by 2030, according to a new report by Vision Research Reports.

The global diabetes associated ophthalmic treatment market size was valued at US$ 28.2 billion in 2020 and is anticipated to grow at a CAGR of 7.5% during forecast period 2021 to 2030.

Diabetes Associated Ophthalmic Treatment

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38804

Diabetes Associated Ophthalmic Treatment Market Growth Factors

 The increasing prevalence of type II diabetes, geriatric population, and availability of early detection techniques are some of the factors driving the growth. This is coupled with technological advancements and increasing awareness of early diagnostics to help increase the success rate of the available treatment options. An increasing number of clinical trials to assess new drugs and devices for the prevention and management of these ophthalmic conditions are expected to fuel market growth in upcoming years.

 An increasing number of initiatives being undertaken by governments and nonprofit organizations to increase diabetes associated ophthalmic disease awareness is expected to boost the adoption of devices used for the treatment. Furthermore, WHO and IDF are working together to prevent and control diabetes and ensure good quality of life for people worldwide by providing accessible treatment facilities.

Diabetes Associated Ophthalmic Treatment Market Report Coverage
Report Scope Details
Market Size US$ 50.7 Bn by 2030
Growth Rate CAGR of 7.5% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Type, application; end-use
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Alcon; Johnson & Johnson Services, Inc.; Bausch Health; Allergan; Bayer AG; Santen Pharmaceutical Co. Ltd.; Novartis AG; Pfizer, Inc.; Genentech, Inc.; Carl Zeiss Meditec; Lumenis; Ellex Medical Lasers Ltd.; IRIDEX Corporation; Topcon Corporation; Abbott Medical Optics; Quantel
By Type Analysis

The drugs segment dominated the market for diabetes associated ophthalmic and accounted for the largest revenue share of 58.6% in 2020. The drug segment comprises anti-glaucoma drugs, anti-inflammatory drugs, anti-VEGF drugs, anti-allergy drugs, and others.

The devices segment is growing at a rapid pace accounted for a CAGR of 6.4% during the forecast period. The devices segment comprises refractive error surgical devices, glaucoma surgical devices, cataract surgical devices, vitreoretinal surgical devices, diagnostic devices, and visual aid devices.

By End-use Analysis

The hospital segment dominated the market for diabetes associated ophthalmic and accounted for the largest revenue share of 39.4% in 2020. An increasing number of hospital admissions of diabetes patients are boosting the demand for the segment,

By Application Analysis

The diabetic retinopathy segment dominated the market for diabetes associated ophthalmic and accounted for the largest revenue share of around 26.0% in 2020. Diabetic retinopathy is considered a critical medical condition that impacts the eyes of the patient leading to vision loss.

increasing clinical trials for the approval of drugs used for the treatment of diabetic retinopathy is expected to boost the growth of the market for diabetes associated ophthalmic.

By Regional Analysis

North America dominated the diabetes associated ophthalmic treatment market and held the largest revenue share of 37.5% in 2020. The growth in the region is mainly attributed to factors such as robust healthcare infrastructure,

 In Asia Pacific, the market for diabetes associated ophthalmic is expected to witness the fastest growth rate during the forecast period. The growing ophthalmic disorders burden and rising consumer awareness are expected to drive the market for diabetes associated ophthalmic in the region.

Read also @ Healthcare Cyber Security Market to Reach US$ 44.5 Bn by 2030

Major Key Players Covered in The Diabetes Associated Ophthalmic Treatment Market Report include
  • Alcon
  • Johnson & Johnson Services, Inc.
  • Bausch Health
  • F. Hoffmann-La Roche Ltd
  • Allergan
  • Bayer AG
  • Santen Pharmaceutical Co. Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Genentech, Inc.
  • Carl Zeiss Meditec
  • Lumenis
  • Ellex Medical Lasers Ltd.
  • IRIDEX Corp.
  • Topcon Corp.
  • Abbott Medical Optics
  • Quantel
Diabetes Associated Ophthalmic Treatment Market Segmentation
  • By Application
    • Dry Eye Syndrome
    • Glaucoma
    • Eye Allergy & Infection
    • Diabetic Retinopathy
    • Diabetic associated Macular Degeneration
    • Uveitis
    • Cataract
    • Diabetic Macular Edema
    • Others
  • By Type
    • Drugs
    • Devices
  • By End-use
    • Hospitals
    • Ophthalmic Centers
    • Ambulatory Surgical Centers
    • Others
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Diabetes Associated Ophthalmic Treatment Market Snapshot

Chapter 4.  Diabetes Associated Ophthalmic Treatment Market Variables and Scope

4.1.  Introduction

4.2.  Diabetes Associated Ophthalmic Treatment Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Application Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Diabetes Associated Ophthalmic Treatment Market Dynamics Analysis and Trends

5.1.  Diabetes Associated Ophthalmic Treatment Market Dynamics

5.1.1.    Diabetes Associated Ophthalmic Treatment Market Drivers

5.1.2.    Diabetes Associated Ophthalmic Treatment Market Restraints

5.1.3.    Diabetes Associated Ophthalmic Treatment Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Diabetes Associated Ophthalmic Treatment Market, By Type

7.1.  Diabetes Associated Ophthalmic Treatment Market, by Type, 2021-2030

7.1.1.    Drugs

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Devices

7.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Diabetes Associated Ophthalmic Treatment Market, By Application

8.1.  Diabetes Associated Ophthalmic Treatment Market, by Application, 2021-2030

8.1.1.    Dry Eye Syndrome

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Glaucoma

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Eye Allergy & Infection

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Diabetic Retinopathy

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Diabetic associated Macular Degeneration

8.1.5.1.        Market Revenue and Forecast (2017-2030)

8.1.6.    Uveitis

8.1.6.1.        Market Revenue and Forecast (2017-2030)

8.1.7.    Cataract

8.1.7.1.        Market Revenue and Forecast (2017-2030)

8.1.8.    Diabetic Macular Edema

8.1.8.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Diabetes Associated Ophthalmic Treatment Market, By End-use

9.1.  Diabetes Associated Ophthalmic Treatment Market, by End-use, 2021-2030

9.1.1.    Hospitals

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Ophthalmic Centers

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Ambulatory Surgical Centers

9.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Diabetes Associated Ophthalmic Treatment Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Type (2017-2030)

10.1.2.  Market Revenue and Forecast, by Application (2017-2030)

10.1.3.  Market Revenue and Forecast, by End-use (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Type (2017-2030)

10.2.2.  Market Revenue and Forecast, by Application (2017-2030)

10.2.3.  Market Revenue and Forecast, by End-use (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Type (2017-2030)

10.3.2.  Market Revenue and Forecast, by Application (2017-2030)

10.3.3.  Market Revenue and Forecast, by End-use (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Type (2017-2030)

10.4.2.  Market Revenue and Forecast, by Application (2017-2030)

10.4.3.  Market Revenue and Forecast, by End-use (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Type (2017-2030)

10.5.2.  Market Revenue and Forecast, by Application (2017-2030)

10.5.3.  Market Revenue and Forecast, by End-use (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by End-use (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by End-use (2017-2030)

Chapter 11.  Company Profiles

11.1.              Raphas

11.1.1.  Company Overview

11.1.2.  Type Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Novartis International AG

11.2.1.  Company Overview

11.2.2.  Type Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Becton Dickinson and Company

11.3.1.  Company Overview

11.3.2.  Type Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              B. Braun

11.4.1.  Company Overview

11.4.2.  Type Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Nanopass Technologies Limited

11.5.1.  Company Overview

11.5.2.  Type Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Termo

11.6.1.  Company Overview

11.6.2.  Type Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Smiths Medical

11.7.1.  Company Overview

11.7.2.  Type Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Cardinal Health

11.8.1.  Company Overview

11.8.2.  Type Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              3M

11.9.1.  Company Overview

11.9.2.  Type Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38804

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: [email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *